Global Mono Hepatitis B Vaccine Sales Market Report 2021

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.

Market Analysis and Insights: Global Mono Hepatitis B Vaccine Market
The global Mono Hepatitis B Vaccine market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Mono Hepatitis B Vaccine Scope and Market Size
The global Mono Hepatitis B Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mono Hepatitis B Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Yeast Derived
CHO Derived

Segment by Application
Children
Adult

The Mono Hepatitis B Vaccine market is analysed and market size information is provided by regions (countries). Segment by Application, the Mono Hepatitis B Vaccine market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute